| Budget Amount *help |
¥3,810,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥210,000)
Fiscal Year 2007: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2006: ¥2,900,000 (Direct Cost: ¥2,900,000)
|
|---|
| Research Abstract |
1. Profiling of miRNA
We measured miRNA expression of 30 esophageal cancer with Taqman RTPCR As for miR-21, miR-25, miR-27b, miR-129, miR-130b, and miR-139, high expression was seen in the tumor. As for miR-34b, the expression was not seen in the noncancerous part at all, and a part of appearance was seen only in the cancer part in the case.
Moreover, the case with a high expression was a bad prognosis in miR-23a, miR-26a, miR-27b, miR-96, miR-128b, and miR-129.
PLAG1 and p85a(PIK3R1) are included as a target gene of Has-miR-21, and it is enumerated, and the target of has-miR-34b includes DLL1 the candidate. Next, the gene expression of the target gene of miRNA of a clinical body was measured by using LightCycler, and the relation to the clinical pathology factor etc. was examined. PIK3R1 was a bad prognosis in that in the tumor part high appearance group. In addition, the appearance of DLL1 was seen the prognosis and the relation, and was a bad prognosis in the lower expression group.
2. Analysis of miRNA
The analysis with vector and the RNAi method were performed for miR-21 using esophageal cancer cell lines. As a result, the proliferation of the tumor was inhibited when miR-21 expressed. Therefore, it seems that mir-21 is useful as the target of therapy.
|
